Menu
Enrolling by invitation NCT07203638

Efficacy and Safety of Prophylactic Antibiotics in Preventing Ventilator-associated Pneumonia: A Randomized, Double Blind, Placebo-controlled Trial

No phase Interventional Ventilator-Associated Pneumonia (VAP)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Beta Lactam Antibiotics, Salin.
Who it may be relevant to
Registry conditions: Ventilator-Associated Pneumonia (VAP). Basic parameters: 18 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

Evaluate efficacy and safety of prophylactic antibiotics in preventing early ventilator-associated pneumonia

Interventions

  • Drug Beta Lactam Antibiotics
    Beta lactam cefipim infusion (20mg/kg -12h -2 days ) total volume 10 ml
  • Drug Salin
    Patient will receive .9 % saline (10ml /12h/2days)

Primary outcome measures

  • Ventilation associated pneumonia [Time frame: from the 2nd to the 7th day of mechanical ventilation]

Eligibility criteria

Inclusion criteria

  • • Age > 18 years or older
  • Both sexes will be included.
  • Invasive mechanical ventilation

Exclusion criteria

  • ongoing pneumonia or gross aspiration confirmed by the presence of lung infiltrates on chest radiographs at admission before invasive ventilation
  • previous lung disease precluding accurate interpretation of chest radiographs
  • ongoing antibiotic therapy or during the week before admission
  • known chronic colonization with multidrug-resistant bacteria
  • known allergy to beta-lactam antibiotics
  • Pregnancy

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Triple blind
Primary purpose
Treatment

Study locations

Egypt · 1 center
  • Benha university hospital — Banhā

Identifiers

NCT: NCT07203638 · MD 1-11-2024

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗